Medical marijuana: Tribulations and trials

Journal of Psychoactive Drugs

Volumn 30, Issue 2, 1998, Pages 163-169

  Abrams, Donald I ^a,b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Clinical trial; Marijuana; Protease inhibitors; Safety

Indexed keywords

CANNABIS; DRONABINOL; TETRAHYDROCANNABINOL;

AIDS RELATED COMPLEX; ANOREXIA; CIGARETTE SMOKING; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; REVIEW;

EID: 0031830121     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.1998.10399686     Document Type: Article

References (20)

1. Abrams, D.l.; Child, C.C. & Mitchell, T. 1995. Marijuana, the AIDS wasting syndrome and the U.S. government. New England Journal of Medicine 333:671.
2. Agurell, S.; Halldin, M.; Lindgren, J.; Ohlsson, A.; Widman, M.; Gillespie, H. & Hollister, L. 1986. Pharmacokinetics and metabolism of Δ-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacological Reviews 39 (1): 21-43.
3. Annas, G.J. 1997. Reefer madness—The federal response to California’s medical-marijuana law. New England Journal of Medicine 337:435-39.
4. Cabral, G.A. & Vasquez, R. 1992. Delta-9-tetrahydrocannabinol suppresses macrophage extrinsic antiherpes virus activity. Proceedings of the Society for Experimental Biology andMedicine 199:255-63.
5. Cotton, P. 1992. Government extinguishes marijuana access, advocates smell politics. Journal of the American Medical Association 267:2573-4.
6. Deeks, S.G.; Smith, M.S.; Holodniy, M.H. & Kahn, J.O. 1997. HIV-1 protease inhibitors: A review for clinicians. Journal of the American Medical Association 277: 144-53.
7. Doblin, R.E. & Kleiman, M.A. 1991a. Medical use of marijuana. Annals of Internal Medicine 114:809-10.
8. Doblin, R.E. & Kleiman, M.A. 1991b. Marijuana asantiemetic medicine: A survey of oncologists’ experiences and attitudes. Journal of Clinical Oncology 9:1314-19.
9. Friedman, H.; Klein T.W.; Newton, C. & Daaka, Y. 1995. Marijuana, receptors and immunomodulation. Advances in Experimental Medicine and Biology 373:103-13.
10. Gorter, R.; Seefried, M. & Volberding, P. 1992. Dronabinol effects on weight in patients with HIV infection. AIDS 6:127-9.
11. Grinspoon, L.; Bakalar, J.B. & Doblin, R. 1995. Marijuana, the AIDS wasting syndrome andthe U.S. government. New England Journal of Medicine 333:671.
12. Hall, W.; Solowij, N. & Lemon, J. 1995. The Health and Psychological Consequences of Cannabis Use. National Drug and Alcohol Research Centre, Australia, Monograph series no. 25.
13. Kaiser, J. 1997. In policy change, NIH funds marijuana study. Science 278:211.
14. Kassirer, J.P. 1997. Federal foolishness and marijuana. New England Journal of Medicine 336:366-7.
15. Lehrman, S. 1995. U.S. drug agencies resist AIDS medicinal-pot plan. San Francisco Examiner/Chronicle January 8: I.
16. McCaffrey, B.R. 1996. The Administration’s response to the passage of California Proposition 215 andAnzonaProposition 200. Statement released by Barry R. McCaffrey, Director of the Office of National Drug Control Policy. Executive Office of the President, Washington, D.C., December 30.
17. Mirken, B. 1997. Danger: possible fatal interactions between ritonavir and "ecstacy”, some other psychoactive drugs. AIDS Treatment News Feb 21:265.
18. Steele, F. 1995. Keeping a lid on marijuana research. Nature Medicine 1:853-4.
19. Voelker, R. 1997a. NIH panel says more study is needed to assess marijuana’s medicinal use. Journal of the American Medical Association 277:867-8.
20. Voelker, R. 1997b. “Decent research and closure” needed on medical marijuana, says head ofNIH panel. Journal of the American Medical Association 278:802.